Qiagen N.V..
QGEN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Qiagen N.V. is a global provider of sample to insight solutions. The company develops and markets a comprehensive range of products and services for preanalytical sample preparation, molecular diagnostics, applied testing, and academic and pharmaceutical research. Qiagen's products include consumabl...Show More
Better Health for All
30
QIAGEN's core business delivers exceptional health benefits through molecular diagnostics for infectious diseases, cancer, and other conditions, with over 100 million QuantiFERON-TB tests distributed in 130+ countries
1
and over 100 million women screened for HPV.
2
The company has no reported revenue from harmful products. Its safety record shows no incidents of non-compliance concerning health and safety impacts in 2023,
3
with all manufacturing sites certified to ISO 9001, ISO 13485, MDSAP, and ISO 18385.
4
QIAGEN offers the lowest global price for its products in World Bank-listed low- and middle-income countries and WHO-identified high-burden countries, including need-based donations,
5
and is developing low-cost portable diagnostic platforms for developing countries.
6
For data responsibility, 85% of staff completed data security training,
7
and its main production location is ISO 27001 certified.
8
Fair Money & Economic Opportunity
0
Qiagen N.V. is a global provider of sample to insight solutions, focusing on life sciences and molecular diagnostics. The company's operations, products, and services, as described in the provided articles, do not involve offering lending, deposit, or other consumer financial services. Consequently, all Key Performance Indicators (KPIs) under the 'Fair Money & Economic Opportunity' value, which are designed to assess financial institutions and their provision of financial products, are not applicable to Qiagen N.V. The company does not generate or manage customer finance data, offer consumer credit products, or operate financial service access points.
Fair Pay & Worker Respect
0
No specific quantitative data for the company as a whole is provided for living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.
1
While a 63% reduction in lost working cases due to safety incidents in 2023 compared to 2022 was noted, this is not a recordable occupational injury rate (TRIR) as required by the rubric.
2
Gender pay gap data was provided for a subsidiary (QIAGEN LIMITED), but not for the parent company (QGEN.US).
3
Fair Trade & Ethical Sourcing
-10
On-site quality audits for critical direct suppliers are conducted at least every three years.
1
QIAGEN requires suppliers to commit to its Supplier Code of Conduct, which includes ethical obligations, as a condition for entering contractual relationships, and these principles are part of contractual agreements.
2
Direct suppliers are obliged to allow audits to monitor compliance, and serious violations can lead to the termination of the business relationship.
3
Honest & Fair Business
-20
QIAGEN operates a confidential whistleblower system, the QIAintegrity Line, which includes protection against retaliation for reporting misconduct
1
. The company provides regular employee training on compliance through an eLearning portal
2
. Additionally, QIAGEN has an Anti-Corruption Policy, related compliance policies, and a Corporate Code of Conduct and Ethics
3
. Its compliance program includes regular employee training and third-party due diligence
4
. No specific data is provided for regulatory fines, transparency index scores, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentages, or the extent of independent verification of ethical claims
5
.
Kind to Animals
10
QIAGEN states it does not conduct any animal testing or engage in related activities.
1
The company's Supplier Code of Conduct requires suppliers involved in the use or supply of human and animal biological samples to follow animal research and welfare requirements set forth in the International Guiding Principles for Biomedical Research Involving Animals by CIOMS and the guidelines of AAALAC.
2
Any violation of the Supplier Code of Conduct may result in the termination of the business relationship.
3
No War, No Weapons
0
The company received contracts totaling $3.4 million
1
and $600,000
2
from the U.S. Department of Defense (DOD) and Department of Health and Human Services (HHS) for expanding production capacity of COVID-19 tests and chemical reagents.
3
The articles explicitly state that these contracts are not related to arms or defense, nor do they involve dual-use technology.
4
Therefore, the company has no revenue from arms contracts, no dual-use technology portfolio, no exposure to controversial weapons, and no defense assets requiring divestment.
Planet-Friendly Business
-40
QIAGEN has SBTi-validated targets for net-zero GHG emissions by 2050.
1
These targets include defined interim checkpoints: a 42% reduction in absolute Scope 1 and 2 GHG emissions by 2030, and a 25% reduction in absolute Scope 3 GHG emissions by 2030, both against a 2020 baseline.
2
The company reported no specific regulatory actions, violations, fines, or compliance issues.
3
Respect for Cultures & Communities
20
QIAGEN provides a formal QIAintegrity Line, a digital reporting system accessible to all persons or groups affected by human rights or environmental risks within its operations or supply chains
1
, indicating over 90% coverage of operational sites. This system also serves as a proactive and structured response framework for potential incidents, including those with cultural implications. No cultural appropriation incidents are reported in the provided articles. Community complaints submitted through the QIAintegrity Line are typically resolved within up to 3 months (90 days) on average.
2
Safe & Smart Tech
0
QIAGEN has no recent security news or data leaks mentioned in a vendor risk assessment report.
1
For its Redwood City entity, the company complies with the EU-U.S. Data Privacy Framework, its UK Extension, and the Swiss-U.S. Data Privacy Framework.
2
QIAGEN states it uses strong, industry-accepted encryption technology and protocols to protect individual personal information during transit and storage.
3
The company has a policy to exclusively use personal data to communicate directly with the person in question and will under no circumstance sell or rent personal data to any third party.
4
Users can access, correct, and opt-out of receiving information.
5
Access to electronic information systems requires strong user authentication credentials.
6
QIAGEN provides regular compliance training accessible to all employees
7
and states it collects only necessary data and limits retention periods.
8
Zero Waste & Sustainable Products
-40
QIAGEN achieved a 52.74% waste diversion rate in 2024, with 790 tons of waste recycled out of 1,498 tons generated.
1
The QIAamp DNA Mini Kit has an estimated recyclability of over 70% for its main components.
2
In 2022, the company reduced plastic usage by 16.5%.
3
QIAGEN is developing sustainable design guidelines and incorporating circularity into product development, with the QIAwave product line being the first to use recycled plastics and space-saving chemical concentrates.
4
The company implements waste hierarchy principles at its sites, has a Plastic Footprint Task Force, and is exploring initiatives like a pilot study on pyrolysis for plastic waste.
5
Hazardous waste is managed according to local regulations.
6
No waste disposal violations were reported in 2023 or 2024.
7
QIAGEN has waste reduction targets for 2030, but specific percentages are not publicly provided.
8
The company provides recycling instructions on product packaging and offers an online tool to help customers calculate waste savings.
9
QIAwave packaging uses FSC-certified cardboard and recycled materials, achieving approximately 77% recycled content.
10